Drug Information

Drug General Information
Drug ID
D0Z8RH
Former ID
DNC009065
Drug Name
2-Benzyl-3-phenyl-7-(trifluoromethyl)-2H-indazole
Drug Type
Small molecular drug
Indication Discovery agent Investigative [529781]
Structure
Download
2D MOL

3D MOL
Formula
C21H15F3N2
Canonical SMILES
C1=CC=C(C=C1)CN2C(=C3C=CC=C(C3=N2)C(F)(F)F)C4=CC=CC=C4
InChI
1S/C21H15F3N2/c22-21(23,24)18-13-7-12-17-19(18)25-26(14-15-8-3-1-4-9-15)20(17)16-10-5-2-6-11-16/h1-13H,14H2
InChIKey
LGRUCHCYEMOENE-UHFFFAOYSA-N
PubChem Compound ID
25137977
Target and Pathway
Target(s) Oxysterols receptor LXR-alpha Target Info Inhibitor [529781]
Oxysterols receptor LXR-beta Target Info Inhibitor [529781]
KEGG Pathway PPAR signaling pathway
Non-alcoholic fatty liver disease (NAFLD)
Hepatitis C
Pathway Interaction Database RXR and RAR heterodimerization with other nuclear receptorrxr_vdr_pathway:RXR and RAR heterodimerization with other nuclear receptor
Reactome Nuclear Receptor transcription pathway
WikiPathways Nuclear Receptors in Lipid Metabolism and Toxicity
Nuclear Receptors Meta-Pathway
PPAR Alpha Pathway
Liver X Receptor Pathway
Adipogenesis
SREBF and miR33 in cholesterol and lipid homeostasis
Nuclear ReceptorsWP1982:SREBP signalling
Nuclear Receptors
References
Ref 529781J Med Chem. 2008 Nov 27;51(22):7161-8.Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic triglyceride synthesis.
Ref 529781J Med Chem. 2008 Nov 27;51(22):7161-8.Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic triglyceride synthesis.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.